PE20000944A1 - Derivados de sulfonamida - Google Patents

Derivados de sulfonamida

Info

Publication number
PE20000944A1
PE20000944A1 PE1999000767A PE00076799A PE20000944A1 PE 20000944 A1 PE20000944 A1 PE 20000944A1 PE 1999000767 A PE1999000767 A PE 1999000767A PE 00076799 A PE00076799 A PE 00076799A PE 20000944 A1 PE20000944 A1 PE 20000944A1
Authority
PE
Peru
Prior art keywords
alkyl
disorder
azethydinyl
pyrrolidinyl
nitro
Prior art date
Application number
PE1999000767A
Other languages
English (en)
Inventor
Richard Lee Simon
Winton Dennis Jones
Hamideh Zarrinmayeh
Andrew Hendley Fray
Dennis Michael Zimmerman
Paul Leslie Ornstein
Macklin Brian Arnold
David Michael Bender
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20000944A1 publication Critical patent/PE20000944A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/04—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE SULFONAMIDA DE FORMULA (R1)(Ra)(Rb)-C-CH2-NHSO2R2, DONDE UNO O DOS DE Ra Y Rb SON F, CF3, -ORc; Rc ES H, ALQUILO C1-C4, Y EL OTRO ES H o FORMAN JUNTOS =O, =CH2; R1 ES NAFTILO, FENILO, FURILO, TIENILO, PIRIDILO OPCIONALMENTE SUSTITUIDO POR 1-2 HALOGENO, NITRO, ALQUILO C1-C10, (CH2)yX1R9, ENTRE OTROS; y ES 0-4; X1 ES O, S, NR10, CO, CONR11, NR12CO, OCONR13, ENTRE OTROS; R9 ES H, ALQUILO C1-C10, ALQUENILO C3-C10, ENTRE OTROS; R10, R11, R12, R13 SON H, ALQUILO C1-C10 o R9, R10, R11, R12 O R13 FORMAN JUNTO CON N UN GRUPO AZETIDINILO, PIRROLIDINILO, PIPERIDINILO, R14-(La)n-X2-(Lb)m, ENTRE OTROS; X2 ES UN ENLACE, O, NH, S, SO, SO2, ENTRE OTROS; La Y Lb SON ALQUILENO C1-C4; UNO DE n Y m ES 0-1 Y EL OTRO ES 0; R14 ES FENILO, ANILLO HETEROAROMATICO OPCIONALMENTE SUSTITUIDO POR HALOGENO, NITRO, CIANO, (CH2)zX3R15; ENTRE OTROS; z ES 0-4; X3 ES O, S, NR16, CO, ENTRE OTROS; R2 ES ALQUILO C1-C6, CICLOALQUILO C3-C6, NR3R4, ENTRE OTROS; R3 Y R4 SON ALQUILO C1-C4 O JUNTO CON N FORMAN UN GRUPO AZETIDINILO, PIRROLIDINILO, PIPERIDINILO. UN COMPUESTO PREFERIDO A. EL DERIVADO DE SULFONAMIDA ES UN POTENCIADOR DEL RECEPTOR DE GLUTAMATO POR LO QUE PUEDE SER UTIL PARA TRATAR UN TRASTORNO COGNITIVO, TRASTORNO NEURODEGENERATIVO, DEMENCIA, DEBILITAMIENTO DEBIDO A LA EDAD, TRASTORNO DEL MOVIMIENTO, MEJORAR LA MEMORIA Y APRENDIZAJE
PE1999000767A 1998-07-31 1999-07-27 Derivados de sulfonamida PE20000944A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9490598P 1998-07-31 1998-07-31

Publications (1)

Publication Number Publication Date
PE20000944A1 true PE20000944A1 (es) 2000-09-20

Family

ID=22247857

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000767A PE20000944A1 (es) 1998-07-31 1999-07-27 Derivados de sulfonamida

Country Status (9)

Country Link
EP (1) EP0980864A3 (es)
JP (1) JP2002521443A (es)
AR (1) AR021745A1 (es)
AU (1) AU5239799A (es)
CA (1) CA2338864A1 (es)
CO (1) CO5080788A1 (es)
PE (1) PE20000944A1 (es)
SV (1) SV1999000115A (es)
WO (1) WO2000006157A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9702194D0 (en) 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
US6693137B1 (en) 1998-07-31 2004-02-17 Eli Lilly And Company Sulphonamide derivatives
IL146052A0 (en) 1999-04-30 2002-07-25 Lilly Co Eli Monofluoroalkyl derivatives
WO2001089510A2 (en) * 2000-05-24 2001-11-29 Eli Lilly And Company Use of an ampa receptor potentiator for the treatment of obesity
ES2236321T3 (es) * 2000-10-13 2005-07-16 Eli Lilly And Company Procedimiento para el tratamiento de la apoplejia.
JP2004511540A (ja) 2000-10-13 2004-04-15 イーライ・リリー・アンド・カンパニー シクロアルキルフルオロスルホンアミド誘導体
RU2403242C2 (ru) * 2004-08-09 2010-11-10 Глэксо Груп Лимитед Соединения, которые усиливают рецептор глутамата, и их применение в медицине
WO2010115952A1 (en) * 2009-04-09 2010-10-14 N.V. Organon Indane derivatives
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2721031B1 (en) 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9624244B2 (en) 2012-06-06 2017-04-18 Constellation Pharmaceuticals, Inc. Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
JP2016521755A (ja) 2013-06-13 2016-07-25 ヴェロサイエンス，リミテッド・ライアビリティー・カンパニー 代謝障害を治療するための組成物および方法
CA2952830C (en) 2014-06-20 2022-11-01 Constellation Pharmaceuticals, Inc. Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876346A (en) * 1985-05-02 1989-10-24 American Home Products Corporation Quinoline compounds
DE68909958D1 (de) * 1988-01-19 1993-11-25 Tanabe Seiyaku Co Phenoxyessigsäure-Derivate, ihre Herstellung, pharmazeutische Zusammensetzungen, die sie enthalten, und deren Verwendung.
DE3819052A1 (de) * 1988-06-04 1989-12-07 Basf Ag Neue sulfonamid-derivate, ihre herstellung und verwendung
DE4114330A1 (de) * 1991-05-02 1992-11-05 Basf Ag Neue arzneimittelkombination
GB9702194D0 (en) * 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives

Also Published As

Publication number Publication date
AU5239799A (en) 2000-02-21
EP0980864A3 (en) 2003-07-09
JP2002521443A (ja) 2002-07-16
EP0980864A2 (en) 2000-02-23
CO5080788A1 (es) 2001-09-25
AR021745A1 (es) 2002-08-07
SV1999000115A (es) 2000-04-11
WO2000006157A1 (en) 2000-02-10
CA2338864A1 (en) 2000-02-10

Similar Documents

Publication Publication Date Title
PE20000942A1 (es) Derivados de amida, carbamato y urea
PE20000944A1 (es) Derivados de sulfonamida
ATE145898T1 (de) Verwendung von sulfonamiden als heilmittel und neue sulfonamide
CO4950558A1 (es) Moduladores de receptores de aminoacidos excitadores
PE72899A1 (es) Derivados sulfonamida
CO4900059A1 (es) 3- ureido-piridofuranos y- piridotiofenos
ES2159839T3 (es) Derivados del propano, su preparacion y su uso.
GB1063894A (en) Quinazolinedione derivatives
AR040346A2 (es) Compuestos intermediarios para la sintesis de benzamido-piperidinas
AR017111A1 (es) Composiciones detergentes para el lavado de ropa con polimeros a base de aminas lineales para proporcionar beneficios en cuanto a aspecto exterior eintegridad a las telas lavadas con las mismas
PE106499A1 (es) Antagonistas del receptor ccr-3
AR015763A1 (es) Indolinonas sustituidas y sus sales fisiologicamente compatibles, un procedimiento para su preparacion, su empleo para la preparacion de un medicamento, losmedicamentos que las contienen y un procedimiento para la preparacion de estos medicamentos
CO4940442A1 (es) Derivados de 4-bromo o 4-yodo fenilamino acido benzhidroxamico
DK0955299T3 (da) Nye derivater af benzothiophen, benzofuran og indol, fremgangsmåde til fremstillingen heraf og sammensætninger, som indeholder disse
AR013693A1 (es) Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria
PE20061297A1 (es) Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
CO4970713A1 (es) Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
AR064517A1 (es) Pirimidinionas biciclicas y sus usos
ES2113368T3 (es) Antagonistas de serotonina.
TR199801734T2 (xx) Yeni arilglisinamid t�revleri, �retim y�ntemleri.
DK157295C (da) Tetrahydrobenzindoler og deres anvendelse som laegemidler
PE20010117A1 (es) Derivados monofluoroalquilo que potencian la funcion de los receptores de glutamato
AR017542A1 (es) Compuestos [indol]naftopiranos, procedimiento para prepararlos, un (co)polimero, un compuesto fotocromatico, una composicion fotocromatica, una matriz(co)polimerica, un articulo solar y un vidriado, todos basados en los compuestos
AR039122A1 (es) Derivados de ftalimido como inhibidores de monoamino oxidasa b
AR015514A1 (es) Compuesto de amida, proceso para su preparacion y composicion farmaceutica que lo contiene

Legal Events

Date Code Title Description
FC Refusal